A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Bb-21217 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors bluebird bio
- 21 Feb 2018 According to a bluebird bio media release, company anticipates to present the clinical data from this study at the ASH Annual Meeting 2018.
- 28 Sep 2017 According to a bluebird bio media release, first patient has been treated.
- 11 Sep 2017 New trial record